The gene encoding human plakoglobin was mapped to chromosome 17ql2-q22. An intragenic restriction fragment length polymorphism was used to localize the plakoglobin gene distal to locus KRTIO and proximal to the marker D17S858. The plakoglobin gene colocalizes with the polymorphic 17q21 marker UM8 on the same cosmid insert. This subregion of chromosome 17 is known to be particularly subjected to genetic alterations in sporadic breast and ovarian tumors. We show loss of heterozygosity of the plakoglobin gene in breast and ovarian tumors. We have identified a lowfrequency polymorphism in the plakoglobin coding sequence which results in an arginine to histidine substitution at amino acid position 142 of the protein, as well as a silent mutation at nucleotide position 332 of the coding sequence. This polymorphism allowed us to demonstrate an allelic association of plakoglobin with predisposition to familial breast and ovarian cancers. Our results, together with the present knowledge about the biological function of plakoglobin, suggest that plakoglobin might represent a putative tumor suppressor gene for breast and ovarian cancers.
Plakoglobin was first identified in purified desmosomal preparations, and the coding sequence for human plakoglobin has been determined (1, 2) . Desmosomes serve as membraneattachment sites for intermediate filaments, and plakoglobin associates with the cytoplasmic region of desmoglein I, one of the transmembrane desmosomal proteins (3) . More recently, it has become evident that plakoglobin is also a component of the cadherin-catenin complex, which is predominantly localized where actin filaments anchor in adherens junctions of epithelial cells (4) (5) (6) . Catenins have been identified in association with the Ca2+-dependent cell adhesion molecule, Ecadherin (uvomorulin), and have been termed a-, 1-, and y-catenin, with Mr of 102, 88, and 80 kDa, respectively (7) . Molecular cloning and comparison of primary structures revealed similarities of catenins with other peripheral cytoplasmic proteins known to be localized in prominent cell-contact sites. a-Catenin is homologous with vinculin, ,B-catenin is homologous with plakoglobin and the protein of the Drosophila armadillo gene, while y-catenin is very likely identical to plakoglobin (for review, see ref. 8) . Catenins are of central importance for cadherin function. They mediate the connection of cadherins to actin filaments and are part of a higher order submembranous network by which cadherins are linked to other transmembrane and peripheral cytoplasmic proteins. Of particular interest are recent results indicating that ,B-catenin mediates the interaction of the cadherin-catenin complex
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with the epidermal growth factor (EGF) receptor and that ,B-catenin and plakoglobin are substrates for tyrosine phosphorylation following EGF stimulation of cells (9) . These results, together with the finding that catenins are associated with the tumor suppressor protein APC, open the possibility that catenins might be involved in signaling pathways and tumorigenesis (10) .
We have recently used the cDNAs encoding mouse caE-and ,B-catenin and mouse plakoglobin to map the respective genes in the mouse genome (11) . We found that the aE-catenin gene maps to chromosome (chr) 18 , the 3-catenin gene maps to chr 9, and the plakoglobin gene maps to chr 11 close to the HoxB cluster. For the chromosomal localization of aE-and f-catenin, these results are in agreement with the assignment of the respective human genes to chr 5q31 and chr 3p2l (12, 13 Cloning of Plakoglobin cDNA from Tumor Tissue. To clone the full-length plakoglobin gene from tumor tissue, the transcript was divided into three parts. The N-terminal coding part (aa 1-246) was amplified from reversed-transcribed RNA with primer pair Plakol20 (5'-ATATGGATCCATGGAGGT-GATGAACCTGATGG) and Plako856r (5'-TGGCATA-GAACAGGACCGACTC) and inserted into the BamHI/Sph I restriction sites of pQE40 (Diagen, Hilden, Germany). The core coding region (aa 221-659) was amplified with primer pair Plako779 (5' -CGCCATCTTCAAGTCGGG) and Plako2O96r (5'-GTCTGGGTTCTTGTCCTC), double digested with Sph I and Bgl II, and inserted into the corresponding sites of pQE40. The C-terminal coding part (aa 554-745) was amplified with primer pair Plakol778 (5'-TGTGAGGAT-GGAGGAGATTGTGG) and Plako2539r (5'-ACCAAAGA-CACAATAAGAAGGCAG), double digested with Bgl II and Xba I, and inserted into the corresponding sites of pBluescript II SK(+) (Stratagene). Five independent plasmid clones were sequenced from each region.
Sequencing Analysis. Plasmid clones were sequenced by using a Sequenase 2.0 kit (United States Biochemical) or an automated sequencer (ALF, Pharmacia). Primers were complementary to flanking vector sequences or to plakoglobin cDNA. Primers for automated sequencing were fluorescein labeled. PCR products were purified with JetPure PCR purification kit (Genomed, New York) and were directly sequenced by using nested primers or, in some cases, the same primers as used for PCR. Heat-denatured PCR products were placed into liquid nitrogen for 2 min, and sequencing primers were pipetted onto the frozen sample. Samples were then thawed slowly to room temperature, and sequencing procedures were carried out by using the Sequenase 2.0 kit. Dried sequencing gels were exposed to Kodak XAR film at room temperature for 1-3 days.
Amplification of Exons 2-5. Plakoglobin N-terminal coding exons 2-5 from affected persons of 13 different BRCAJ families were amplified by PCR with primers binding to flanking intron sequences and sequenced directly. The exonspecific primers used were as follows: exon 2, E2F-77 (5'-CGGAATTCGTGACGGGCTGAAGCTG) and E2R+87 (5'-AGCGGATCCTGCCTCCTTTCACTCTGAC); exon (Fig. 1) . Mouse and hamster DNA were included as controls, and hybridization and washing were carried out under highstringency conditions. Plakoglobin is evolutionarily well conserved, and homologs have been isolated by cross-species hybridization (20) . As seen in Fig. 1 , human plakoglobin cDNA hybridizes to human DNA but also to mouse and hamster DNA. However, the results obtained with DNA from hybrid cells unambiguously demonstrate that the human plakoglobin gene maps to chr 17ql2-q22. The previously reported localization of plakoglobin to human chr 7 (14) was based on PCR analysis using synthetic oligonucleotides and is not confirmed by our independent experimental approach.
Plakoglobin bin gene at the proximal border of the breast cancer region in close physical proximity (<40 kb) to the 17q21 marker locus UM8 (Fig. 2) . Arginine/Histidine Polymorphism. Plakoglobin-positive clones isolated from a human genomic library in EMBL3A allowed us to identify intron/exon boundaries of exons 2-5 of the plakoglobin gene (data not shown). Synthetic oligonucleotides flanking the intron/exon boundaries were used to amplify individual exons, which were then subjected to direct sequence analysis. In this way, sequence information was obtained from 20 (13 for exons 2 and 3 and 7 for exons 4 and 5) independent breast cancer families. No changes in the nucleotide sequences were observed for exons 2, 4, or 5. However, in 2 of 13 families (families F1816 and F2619), heterozygosity at nucleotide position 544 in exon 3 was observed, leading to the substitution of arginine (CGC) by histidine (CAC) at amino acid position 142 (designated R142H) (Fig. 3A) . This base-pair substitution led to a loss of the recognition sites for restriction enzymes BstU1 and Hha I and thereby created a new RFLP which was convenient to use to follow the segregation of this allele in breast cancer families (Fig. 3B) -strand + strand 3' (327) 5 
506- and from tumor material of ind. 13 from BRCA1-linked family F2619 was reverse transcribed and PCR amplified by using primer pair Plakol20 and Plako856r. The PCR product from the His-142 allele was most abundant in material amplified from the tumor, and the minor bands corresponding to transcripts from the Arg-142 allele may well be derived from nontumor cells-i.e., interstitial and/or endothelial cells.
in three different segments. Since an amplification of plakoglobin mRNA from nontumor cells-i.e., interstitial cells and blood vessels-could not be completely ruled out, five independent clones were sequenced from each portion. Remarkably, only sequences transcribed from the His-142 allele were obtained. In agreement with this result, when the primary reverse transcription-PCR product was digested with restriction enzyme Hha I, most of the transcripts detected were from the His-142 allele (Fig. 3C) . The low-abundance transcripts from the Arg-142 allele seen in Fig. 3Cwere most likely derived from plakoglobin mRNA of nontumor cells. The results suggest that the plakoglobin gene is subjected to LOH in tumor cells from this individual.
A LOH for the plakoglobin gene was also identified in an individual (no. 3) from breast cancer family F2770 from whom germ-line DNA, as well as DNA and mRNA from a breast tumor, was available for comparison. Family F2770 is not polymorphic for the R142H substitution, but was heterozygous for a silent mutation in the germ line (Fig. 4A) . The silent mutation induced a new RFLP for restriction enzyme BstEII, and this allele was again found to segregate in family F2770 with haplotypes associated with genetic breast cancer predisposition (Fig. 4B) . Sequence comparison of the germ-line and tumor DNA from individual 3 revealed LOH for the plakoglobin gene in the tumor DNA (Fig. 4A) . Concordant with this, when primary reverse transcription-PCR products were digested with restriction enzyme BstEII most of the transcripts were from the allele carrying the silent mutation (Fig. 4C) . The low-abundance transcript from the other allele is again likely to be derived from nontumor cells since this tumor contained about 30% interstitial cells and blood vessels, as judged by histological examination. Cloning and sequencing of plakoglobin cDNA by using a strategy similar to that described above for the F2619 tumor demonstrated that only transcripts from the allele carrying the silent mutations were detectable. Thus, the results from two independent BRCAJ-linked families demonstrate that the plakoglobin gene is subject to (24) . We have identified a polymorphism of the gene which resulted in an Arg-142 --> His substitution. This is a low-frequency polymorphism since only 10 chromosomes contained the His-142 allele from a total of 240 randomly tested chromosomes. The biological implication of this polymorphism is presently not well understood and is somewhat unexpected since plakoglobin is considered to be a structural gene which is highly conserved during evolution (20) . The arginine residue is particularly well conserved in different species from man to hydra and is located within or very close to the a-cateninbinding site in plakoglobin (H. Schwartz, H.A., and R.K., unpublished observation). Interestingly, the low-frequency His-142 allele segregated in breast cancer families with marker loci for genetic breast cancer predisposition. This suggests that the BRCAJ gene might be associated with a particular plakoglobin allele. Finally, we demonstrate that the plakoglobin gene is subjected to LOH in breast and ovarian tumors.
Our results must be discussed in light of the accumulating data provided by an international effort to characterize the genetic predisposition for breast and ovarian tumor development. The BRCA1 gene has recently been identified and very likely encodes a nucleic acid-binding protein since the protein contains a zinc-finger domain (19) . The search for mutations in the BRCAJ gene in sporadic breast and ovarian carcinomas led to the identification of mutations in the BRCA1 gene in 4 of 44 cases (25) . However, the four mutations all turned out to be germ-line alterations, and no somatic mutations were detected, which raises the possibility that other tumor suppressor genes on chr 17q incidentally included in the breast cancer region may contribute to tumor development. Recently, Albertsen et al. (21) have proposed that two separate loci on 17ql2-q21 are equally important in breast cancer development. In addition, analysis of LOH in sporadic breast tumors defined a minimal region centering around the GAS locus (24) . We know that the plakoglobin gene is located in this region since both GAS and UM8 have been found on the same P1 clone (21) . These findings, together with our results, open the possibility that plakoglobin may represent a susceptibility gene for sporadic breast and ovarian cancers. This view is supported by current knowledge about the biological function of plakoglobin: (i) plakoglobin is a component of the cadherin-catenin complex (4-6); (ii) plakoglobin and f3-catenin are phosphorylated at tyrosine residues after EGF-stimulation of cells, and f3-catenin (and most likely plakoglobin) mediate(s) the interaction of the cadherin-catenin complex with the EGFreceptor (9) ; and (iii) plakoglobin and a-and ,B-catenin have been found in association with the tumor suppressor protein APC (10) . Catenins might represent more general linker proteins involved in connecting membrane receptors with the cytoskeleton. They are also likely to be part of signal-transduction pathways. Obviously, mutations in these molecules could have dramatic effects on cell morphology and cell proliferation. It is intriguing to note that the genes for both ,B-catenin and plakoglobin map' to chromosomal regions known to represent hot spots of genetic alterations, such as LOH. We have shown here that plakoglobin localizes to the breast cancer region and that the gene for f3-catenin was mapped to human chr 3p21 (13), a genetic region known to be affected during lung carcinogenesis.
